Company: BDRX
Filing Date: 2025-05-12
Form Type: 424B3
Source: 0001214659-25-007341
Chunk: 11

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-12
Form: 424B3
Chunk 11
---
anticipate,” “plan,” “estimate,” “intend,” “should,” “can,” “likely,”
“could” and similar expressions are intended to identify forward-looking statements. Forward-looking statements appear in
a number of places throughout this prospectus and include statements regarding our intentions, beliefs, assumptions, projections, outlook,
analyses or current expectations concerning, among other things, our intellectual property position, success integrating acquisitions,
research and development projects, results of operations, cash needs, capital expenditures, financial condition, liquidity, prospects,
growth and strategies, regulatory approvals and clearances, the markets and industry in which we operate and the trends and competition
that may affect the markets, industry or us.

These forward-looking statements
are based on currently available competitive, financial and economic data together with management’s views and assumptions regarding
future events and business performance as of the time the statements are made and are subject to risks and uncertainties. We wish to caution
you that there are some known and unknown factors that could cause actual results to differ materially from any future results, performance
or achievements expressed or implied by such forward-looking statements, including but not limited to risks related to:

| · | our requirement for additional financing and our ability to continue as a going concern; |

| · | our estimates regarding losses, expenses, future revenues, capital requirements and needs for additional 
 financing;                                                                                               |

| · | our ability to successfully develop, test and partner with a licensee to manufacture or commercialize 
 products for conditions using our technology platforms;                                               |

| · | the successful commercialization and manufacturing of our any future product we may commercialize or license; |

| · | the success and timing of our preclinical studies and clinical trials; |

| · | shifts in our business and commercial strategy; |

| · | the filing and timing of regulatory filings, including Investigational New Drug applications, with respect to any of our product candidates 
 and the receipt of any regulatory approvals;                                                                                                |

| · | the anticipated medical benefits of our product candidates; |

| · | the difficulties in obtaining and maintaining regulatory approval of our product candidates, and the labeling 
 under any approval we may obtain;                                                                             |

| · | the success and timing of the potential commercial development of our product candidates and any product 
 candidates we may acquire in the future, including eRapa, tolimidone and MTX110;                         |

| · | our plans and ability to develop and commercialize our product candidates and any product candidates we 
 may acquire in the